CENGILD MEDICAL BERHAD

KLSE (MYR): CENGILD (0243)

You're accessing 15 mins delay data. Turn on live stream now to enjoy real-time data!

Last Price

0.27

Today's Change

0.00 (0.00%)

Day's Change

0.265 - 0.275

Trading Volume

195,900

Financial
Market Cap

Market Cap

225 Million

NOSH

833 Million

Latest Quarter

Latest Quarter

30-Jun-2024 [#4]

Announcement Date

27-Aug-2024

Next Quarter

30-Sep-2024

Est. Ann. Date

24-Nov-2024

Est. Ann. Due Date

29-Nov-2024

QoQ | YoY

-49.98% | -32.04%

T4Q Result

Revenue | NP to SH

66,854.000 | 11,084.000

RPS | P/RPS

8.03 Cent | 3.36

EPS | P/E | EY

1.33 Cent | 20.29 | 4.93%

DPS | DY | Payout %

0.74 Cent | 2.74% | 55.61%

NAPS | P/NAPS

0.13 | 2.02

QoQ | YoY

-6.08% | -16.59%

NP Margin | ROE

16.58% | 9.95%

F.Y. | Ann. Date

30-Jun-2024 | 27-Aug-2024

Latest Audited Result

Latest Audited Result

30-Jun-2024

Announcement Date

30-Oct-2024

Next Audited Result

30-Jun-2025

Est. Ann. Date

30-Oct-2025

Est. Ann. Due Date

27-Dec-2025

Annual (Unaudited)

Revenue | NP to SH

66,854.000 | 11,085.000

RPS | P/RPS

8.03 Cent | 3.36

EPS | P/E | EY

1.33 Cent | 20.29 | 4.93%

DPS | DY | Payout %

0.74 Cent | 2.74% | 55.60%

NAPS | P/NAPS

0.13 | 2.02

YoY

-16.59%

NP Margin | ROE

16.58% | 9.95%

F.Y. | Ann. Date

30-Jun-2024 | 27-Aug-2024

Annualized Result

Revenue | NP to SH

66,854.000 | 11,085.000

RPS | P/RPS

8.03 Cent | 3.36

EPS | P/E | EY

1.33 Cent | 20.29 | 4.93%

DPS | DY | Payout %

-

NAPS | P/NAPS

-

QoQ | YoY

-13.07% | -16.59%

NP Margin | ROE

16.58% | 9.95%

F.Y. | Ann. Date

30-Jun-2024 | 27-Aug-2024

Business Process

Trailing 4 Quarters Trailing 8 Quarters
Available Quarters 4 Quarters 8 Quarters
Continuous Quarters Of Revenue Growth 0 / 4 0.00% 0 / 8 0.00%
Total Positive Profit Years 4 / 4 100.00% 8 / 8 100.00%
Continuous Quarters Of Positive Profit 4 / 4 100.00% 8 / 8 100.00%
Continuous Quarters Of Profit Growth 0 / 4 0.00% 0 / 8 0.00%
Continuous Quarters Of Adjusted EPS Growth 0 / 4 0.00% 0 / 8 0.00%
Total Dividend Years 2 / 4 50.00% 4 / 8 50.00%
Continuous Quarters Of Dividend 1 / 4 25.00% 1 / 8 12.50%
Continuous Quarters Of Dividend Growth 0 / 4 0.00% 0 / 8 0.00%
Continuous Quarters Of Adjusted Dps Growth 1 / 4 25.00% 1 / 8 12.50%
Average ROE 2.54% 2.97%
Average Net Profit Margin 16.48% 17.60%

Last 5 Financial Years Last 10 Financial Years
Available Years 5 Years 10 Years
Continuous Quarters Of Revenue Growth 0 / 4 0.00% 0 / 4 0.00%
Total Positive Profit Years 4 / 4 100.00% 4 / 4 100.00%
Continuous Quarters Of Positive Profit 4 / 4 100.00% 4 / 4 100.00%
Continuous Quarters Of Profit Growth 0 / 4 0.00% 0 / 4 0.00%
Continuous Quarters Of Adjusted EPS Growth 0 / 4 0.00% 0 / 4 0.00%
Total Dividend Years 2 / 4 50.00% 2 / 4 50.00%
Continuous Quarters Of Dividend 2 / 4 50.00% 2 / 4 50.00%
Continuous Quarters Of Dividend Growth 1 / 4 25.00% 1 / 4 25.00%
Continuous Quarters Of Adjusted Dps Growth 2 / 4 50.00% 2 / 4 50.00%
Average ROE 25.86% 25.86%
Average Net Profit Margin 16.46% 16.46%
Key Result

T4Q Annualized Annual (Unaudited) Last 10 FY Average Last 5 FY Average
Revenue 66,854 66,854 66,854 66,261 66,261
NP to SH 11,084 11,085 11,085 10,942 10,942
Dividend 6,163 6,163 6,163 3,068 3,068
Adjusted EPS 1.33 1.33 1.33 1.31 1.31
Adjusted DPS 0.74 0.74 0.74 0.37 0.37

NP to SH = Net Profit Attributable to Shareholder, EPS = Earning Per Share, DPS = Dividend Per Share

All figures in '000 unless specified.

EPS & DPS's figures in Cent.

Growth

LQ QoQ LQ YoY CQ YoY LQ vs Average of T4Q LQ vs Average of T8Q
Revenue -5.31% 2.37% -4.87% -3.40% -5.81%
NP to Owner -49.98% -32.04% -16.59% -45.11% -50.08%
Dividend 0.00% 0.84% 0.84% 100.00% 101.27%
Adjusted EPS -50.70% -33.01% -16.64% -45.75% -50.73%
Adjusted DPS 0.00% 0.84% 0.84% 100.00% 101.27%

LQ = Latest Quarter, CQ = Cumulative Quarter, T4Q = Trailing 4 Quarters, T8Q = Trailing 8 Quarters, QoQ = Quarter on Quarter, YoY = Year on Year

T4Q vs LFY T4Q vs AL5FY T4Q vs AL10FY AQR vs LFY AQR vs AL5FY AQR vs AL10FY LFY YoY LFY vs AL5FY LFY vs AL10FY
Revenue 0.00% 0.89% 0.89% 0.00% 0.89% 0.89% -4.87% 0.89% 0.89%
NP to Owner -0.01% 1.29% 1.29% 0.00% 1.30% 1.30% -16.59% 1.30% 1.30%
Dividend 0.00% 100.84% 100.84% 0.00% 100.84% 100.84% 0.84% 100.84% 100.84%
Adjusted EPS 0.00% 1.25% 1.25% 0.00% 1.25% 1.25% -16.64% 1.25% 1.25%
Adjusted DPS 0.00% 100.84% 100.84% 0.00% 100.84% 100.84% 0.84% 100.84% 100.84%

T4Q = Trailing 4 Quarters, T8Q = Trailing 8 Quarters, AL5FY = Average of Last 5 Financial Years, AL10FY = Average of Last 10 Financial Years, LFY = Latest Financial Year AQR = Annualized Quarter Result, YoY = Year on Year

Discussions
1 person likes this. Showing 50 of 247 comments

LuckyWinForever

Yesyes, so pain buy 0.420 and sold 0.320....sakit...should have set cut loss earlier.

2023-11-03 16:33

faridfet

Price action discount everything means all the information about a company is already reflected in the stock price. Do not against the market.

Do not even think to try accumulate.

Save ur hard earn money.

There is always new opportunity at Bursa.

Cut ur losses and move on.

2023-11-04 00:27

cytew

中了有心人的 “ 草船借箭 ” 之计 !不多久就会慢慢回升了 ! 不需要再惊慌 ...

2023-11-06 17:43

JJFinn

Looking good this morning. Hope it will continue uptread...

2023-11-08 10:33

cytew

Reversal of trend is intact now..

2023-11-10 07:36

Mar2083

May test 35sen today

2023-11-10 08:26

alex

back to 0.31 to make double bottom ...

2023-11-10 16:37

Ahead1268

The PAT quite consistent
Low gearing at 0.26
Not sure how is the Oncology JV announced in Jul23 seen not contributing to revenue.
Revenue also stagnant not much improvement.

2023-11-24 20:26

Chang Keit Siong

Famous goreng group failed and time to look at this company

2023-12-06 19:00

BullxBear

this counter are down trend. up abit then contiune drop . careful. why not move other uptrend stock ?

2023-12-06 21:27

goody99

company is doing ok but its expansion is too slow. It was listed on 2022-4-18. Its IPO proceeds should be used for expansion within 3 years. According to its latest quarterly report, its IPO money is hardly used more than one and half year later.

2023-12-07 13:10

Crrypo

why volume like dead fish, wont move

2023-12-27 11:52

hongheng7

Sad to see company announcement at bursa, need to wait until Dec 2027 ;(

2023-12-29 22:57

shareprofit

Haha, cengild buying property instead of investing in medical business, wtf! Private placements or rights issues soon…DUMP!!!

2024-01-01 19:50

shareprofit

They never heard abt leasing? The same thing that they doing now so successfully. Buying a property? No need take into refurbishment and maintenance cost??? Something damn fishy…can smell from afar. The board members who agreed on this shud be sacked.

2024-01-01 20:00

cytew

看来老板很无知,把值钱的轻资产模式改去不值钱的重资产模式。

2024-01-04 07:34

warchest

Yes, it supposed to be an asset light business model. To have a hospital set-up, it is costly to operate with gestation period of 3 to 5 years upon completion. Focus should be to build its business since it is relatively new healthcare group that was established in 2017

2024-01-04 09:53

warchest

This acquisition should be scrapped. The management should re-think again of its business model. It is costly to operate a hospital without relevant expertise due to its high fixed overhead & capital expenditure & it is an impediment for its to scale up. In total RM180m needs to commit to this expansion plan

2024-01-04 15:51

warchest

It is silly to incur more borrowings to finance this expansion plan

2024-01-04 15:52

SHOB

no worry

2024-01-05 06:54

bgt9963

Rights issue coming......

2024-01-05 08:50

goody99

the next few years (until 2027) are not going to be exciting due to growing pains. If I were you, I would sell now and buy back later

2024-01-05 10:20

SHOB

put it in my safe box see after in mid june

2024-01-06 08:09

geary

SHOB
put it in my safe box see after in mid june
1 week ago
Yup...Invested...@0.32...🤓

2024-01-15 19:49

warchest

The worst performing healthcare in Bursa with almost 50% contraction. I believe many shareholders have doubt of the recent Proposed Acquisition and change of business model from asset light to heavy

2024-02-02 16:49

warchest

first time for many years, I see a healthcare counter that down so much. Typically, healthcare companies should be the most resilient counters

2024-02-02 16:52

WiseEye

CENGILD has been heavily mispriced. There is no reason for the overreaction in the sell-off.

The pivot from renting a building to totally owning one seems highly rationale, given there is a huge business risk if the landlord takes back the property.

As a shareholder, decision to own a building MUST be executed and thoroughly supported. Otherwise, there is a huge cloud of uncertainty with high risks of pushing the company into zero revenue if the building lease cannot be renewed.

2024-02-07 23:03

speakup

i think they should not buy a new building but instead go for a long term lease

2024-02-08 07:41

warchest

They have a bad management team that wobbling around about their business strategy. light business model is a good strategy like in the case of Qualitas and Mediviron with high EBITDA. As a small Group with track record of 2017, it is bad strategy to commit such a high capital expenditure

2024-02-08 16:45

warchest

If this Group is already been more than a decade long, then it is fine but not now. It is a high risk strategy at current juncture as they are still figuring the building blocks

2024-02-08 16:46

Birdie

Mr Warchest, who says Qualitas and Mediviron have a high EBITDA. Their structure is weak, especially Mediviron, and not sustainable. Cengild GI Medical Centre is much better.

2024-02-20 10:57

Birdie

The passing of Dato Dr K L GOH last year ,was a big blow to the Cengild GI Centre.
But now , they still have a very capable team of doctors there.

2024-02-20 16:41

warchest

Good or not, you can analysis both Qualitas & Mediviron business models and financials. You can buy their documents via SSM. So far Cengild is still wobbling with their financials and business model

2024-02-22 11:09

ysyap84

The stock regains its momentum after a short consolidation. (0.30, upon writing)

2024-02-22 15:56

Income

Xi wants to build China industrial industry is so competitive that others simply can't compete with it. Companies still have to invest in China if they want to keep their costs down maintaining their profit margins. At the same time China dominates EV cars industry, solar industry and catching up on chip ...
China takes over the US in terms of nominal GDP is not a matter of if but when. Interesting time ahead.

2024-03-07 00:08

warchest

bad management team that are clueless how to turn around the business

2024-03-19 17:19

bearcomebullgone

aiya lambat sgt mcm usus ni kakkaaaka

2024-06-01 00:55

maltrader

Going to moon

2024-06-05 08:23

Birdie

Stirrings of movement.

2024-06-14 13:36

warchest

useless company

2024-06-19 14:56

cytew

Ya, it is useless now , since they are on the way to change a light assets business model to a heavy assets business model...

2024-07-28 14:45

warchest

They just follow the same model as CVSKL but specialise in Gastrointestinal & Liver Disease

2024-07-31 11:07

warchest

But CVSKL still rented their space. But still they are much more profitable than Cengild. the management team of Cengild is not capable of growing the business but yet not prudent on the Capex spending

2024-07-31 11:10

warchest

lousy management team and not able to grow its earnings

2 months ago

warchest

5 consecutive quarters of contraction in earnings

2 months ago

Unknown404

Cut losses last week haha

2 months ago

Unknown404

I don't understand why not earn that much but still declaring dividend

2 months ago

Post a Comment